Although an early-phase trial failed to show the benefit of CHK1 inhibition in combination with gemcitabine for the treatment of patients with pancreatic cancer, in retrospect, the use of non-platinum chemotherapy limits conclusions about the effectiveness of CHK1 inhibition to induce HRD [171]. This evidence concerns the gene CHEK1 and pancreatic neoplasm.